Sarfo Edward K, Dziemianko Jennifer L, Chen Thomas, Iwaki Kosuke K
Icahn School of Medicine at Mount Sinai, New York, USA.
NYC Health and Hospitals, Elmhurst Hospital Center, New York, USA.
Eur J Case Rep Intern Med. 2024 Jan 25;11(2):004283. doi: 10.12890/2024_004283. eCollection 2024.
Ertapenem, a carbapenem-type beta-lactam antibiotic, demonstrates broad-spectrum efficacy against a wide range of Gram-positive and Gram-negative bacteria, including aerobes and anaerobes. Importantly, it demonstrates resistance to virtually all beta-lactamases, including the extended spectrum beta-lactamases (ESBLs). Haematologic complications such as thrombocytosis, haemolysis, anaemia, and neutropenia are infrequent side effects associated with this drug. In this report, we present a rare case of ertapenem-induced thrombocytosis in a 62-year-old female patient who was admitted for a complicated urinary tract infection caused by .
Ertapenem was identified as the most likely cause of thrombocytosis.Discontinuing ertapenem normalised the platelet count.It is crucial for physicians to identify and address causes of thrombocytosis, particularly when related to medications, to avoid inadvertent complications and to ensure effective patient care.
厄他培南是一种碳青霉烯类β-内酰胺抗生素,对多种革兰氏阳性菌和革兰氏阴性菌具有广谱抗菌活性,包括需氧菌和厌氧菌。重要的是,它对几乎所有β-内酰胺酶都具有耐药性,包括超广谱β-内酰胺酶(ESBLs)。血小板增多、溶血、贫血和中性粒细胞减少等血液学并发症是与该药物相关的罕见副作用。在本报告中,我们介绍了一例62岁女性患者因复杂尿路感染入院,发生厄他培南诱导的血小板增多症的罕见病例。
厄他培南被确定为血小板增多症最可能的病因。停用厄他培南后血小板计数恢复正常。医生识别并处理血小板增多症的病因至关重要,尤其是与药物相关的病因,以避免意外并发症并确保有效的患者护理。